With FDA approval hopefully forthcoming any day now, it’s unlikely we will ever again see a Trading Halt pending a capital raising like this one.
It will be a pleasure to be a shareholder in a unique Australian biotech, which is self-funding it’s leading programs and returning cash to shareholders by way of dividends.
It’s going to be a sleepless few weeks for all concerned including care-givers in the Rett community. Whilst nothing is a certainty with the FDA, my spider tingly senses have me feeling very positive.
GLTAH
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.62 |
Change
-0.340(2.62%) |
Mkt cap ! $1.574B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.62 | $3.846M | 299.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16 | $12.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.63 | 99 | 6 |
View Market Depth
| Last trade - 14.52pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |